Veracyte to Release Second Quarter 2021 Financial Results on July 29, 2021
Veracyte (Nasdaq: VCYT) announced it will release its Q2 2021 financial results after the market closes on July 29. A conference call and webcast will be held at 4:30 p.m. ET on the same day to discuss these results and provide a business update. Participants can access the call through designated dial-in numbers, with a replay available on the company’s website. Veracyte specializes in genomic diagnostics, providing tests for various cancers and diseases, aiming to improve patient care and reduce unnecessary procedures.
- Expanding menu of genomic tests including lung, prostate, breast, and thyroid cancers.
- Exclusive global license to a leading diagnostics instrument platform.
- None.
Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release its financial results for the second quarter of 2021 after the close of market on Thursday, July 29. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day.
The conference call will be webcast live from the company’s website and will be available via the following link: https://edge.media-server.com/mmc/p/ces2j4at. A webcast replay will be available following conclusion of the live broadcast and will be accessible on the company’s website at https://investor.veracyte.com/events-presentations.
The conference call can be accessed as follows: |
|
|
U.S./Canada participant dial-in number (toll-free): |
(855) 541-0980 |
|
International participant dial-in number: |
(970) 315-0440 |
|
Conference I.D.: |
1997209 |
About Veracyte
Veracyte (Nasdaq: VCYT) is a global genomic diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The company’s growing menu of genomic tests leverages advances in genomic science and technology, enabling patients to avoid risky, costly diagnostic procedures and quicken time to appropriate treatment. The company’s tests in lung cancer, prostate cancer, breast cancer, thyroid cancer, bladder cancer and idiopathic pulmonary fibrosis are available to patients and its lymphoma subtyping and renal cancer tests are in development. With Veracyte’s exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its tests to patients worldwide. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).
View source version on businesswire.com: https://www.businesswire.com/news/home/20210708005868/en/
FAQ
When will Veracyte release its Q2 2021 financial results?
What time is the Veracyte conference call for Q2 2021 results?
How can I access the Veracyte Q2 2021 earnings call?
What kind of tests does Veracyte offer?
Where can I find the webcast replay of the Veracyte earnings call?
